Alan Hartman has over 25 years of investment banking experience, having advised on many of the transactions that have helped transformed the healthcare sector over that time. Over the course of his career, Mr. Hartman has advised on almost $1 trillion of transactions, and has established himself as a leading advisor in the healthcare industry. He has advised in some of the largest and most complex transactions across every aspect of the industry, including:
- Large Pharma - Advised Pfizer in multiple transactions including its $68bn acquisition of Wyeth; its $14bn acquisition of Medivation; its $6.7bn acquisition of Arena Pharmaceuticals; its $5bn acquisition of Anacor; its $12bn sale of its nutritional business to Nestlé and its $18bn OTC JV with Glaxo; Astra Zeneca in its $40b acquisition of Alexion and its $15bn acquisition of MedImmune; Merck in its $3bn acquisition of Antelliq and its spinoff of its Organon division;
- Biotech - Advised Seagen in its $44.5bn sale to Pfizer; Advised Immunomedics in its $21bn sale to Gilead Sciences; Pharmacyclics in its $21bn sale to Abbvie; Immunex in its $16bn sale to Amgen and Onyx in its $10bn sale to Amgen; Acceleron in its $11.5b sale to Merck; Cerevel in its $8.7b sale to AbbVie; GW Pharmaceuticals in its $7b sale to Jazz Pharmaceuticals; Mirati in its $5.8bn sale to Bristol-Myers Squibb; Biogen in its defense against Icahn and acquisition of control of Tysabri for $3bn; InterMune in its $9bn sale to Roche; Receptos in its $8bn sale to Celgene; AveXis in its $8bn sale to Novartis; Iveric Bio in its $5.9bn sale to Astellas; Spark in its $5bn sale to Roche; Tesaro in its $5bn sale to Glaxo; Forty Seven in its $4.5bn sale to Gilead; Principia in its $3.7bn sale to Sanofi and Translate Bio in its $3.2b sale to Sanofi
- Specialty Pharma - Mylan in its $25bn merger with Pfizer’s Upjohn division and in $30bn of other acquisitions; Salix’s $16bn sale to Valeant and Questcor in its $6bn sale to Mallinckrodt
- Healthcare Services - The buyout group led by KKR and Bain in the $33bn acquisition of HCA; Omnicare in its $13bn sale to CVS; Alliance Boots in its two-step sale to Walgreens for $25bn; Bergen Brunswig in its $4bn merger with Amerisource; PharmaCord in its $1.5b sale to Permira
- Healthcare REITs - Advised Ventas on over $20bn of deals over a 15 year period, including the acquisition of NHP for $7bn and the spin-off of Care Capital for $4bn and successfully defended the company from an activist proxy fight for board representation
- Medical Devices - Represented Boston Scientific in its $25bn hostile acquisition of Guidant
Mr. Hartman joined Centerview in 2009 after 16 years at Merrill Lynch, where he was head of Americas Mergers & Acquisitions. He received a BS in Economics from the Wharton School of the University of Pennsylvania and a JD from Harvard Law School. He spent four years as a corporate attorney at Skadden Arps prior to joining Merrill Lynch. He is on the Executive Committee of the Board of Weill Cornell Medicine, Vice-Chairman of FARE (Food Allergy Research & Education) and Co-Chairman of the UJA Federation of New York Banking and Finance Committee. Together with his wife and three children, he founded the Fund For New Leadership, a new philanthropic venture that provides early support to emerging social change leaders from cities and towns across the country.